In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico talk about a spate of health-related legislative action on Capitol Hill, including Senate passage of a bill to address the opioid epidemic. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
For families living with dementia, natural disasters can be particularly terrifying, heightening confusion, disorientation, anxiety and paranoia.
A decade ago, California stopped licensing surgery centers and then gave approval power to private accreditors that are commonly paid by the same centers they inspect. That system of oversight has created a troubling legacy of laxity, a Kaiser Health News investigation finds.
Marijuana dispensaries are reaching out to seniors seeking help with the aches and pains of aging. They’re discovering an array of products, and some interesting side effects.
An annual government survey of drug use and health shows a dramatic drop in the number of people who tried heroin but an uptick in pot use.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
In response to a spike in syphilis and gonorrhea cases, one Oregon county is sending medical sleuths to break the bad news in person. Some people have no idea they’ve been exposed to an infection.
The controversy over the death toll from Hurricane Maria continues as the president tweets that the official estimate adopted by territory officials is a political ploy.
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call talk about the Food and Drug Administration’s latest actions to address teenagers’ use of e-cigarettes, Arkansas’ Medicaid work requirements and news about the uninsured from the latest federal Census report.
Embattled drugmaker Purdue Pharma defends OxyContin as some insurers are dropping the drug in favor of other abuse-deterrent opioid painkillers.
